LJ-4517

LJ-4517 is a potent A2AAR antagonist, with a Ki of 18.3 nM. LJ-4517 is potent in displacing the binding of [3H]ZM241385 (HY-19532) at WT A2AAR[1]. LJ-4517 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

CAS Number

[2988849-20-1]

UNSPSC

12352005

Target

Adenosine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/lj-4517.html

Solubility

10 mM in DMSO

Smiles

O[C@H]1[C@H](N2C(C3=CC=CS3)=NC4=C(N)N=C(C#CCCCC)N=C24)OC[C@H]1O

Molecular Formula

C19H21N5O3S

Molecular Weight

399.47

References & Citations

[1]Shiriaeva A, et al. GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A2A Adenosine Receptor. J Med Chem. 2022 Aug 17.